外用红色诺卡氏菌细胞壁骨架制剂(Nr⁃CWS)治疗宫颈上皮内瘤变患者人乳头瘤病毒宫颈持续感染的临床疗效分析  

The clinical efficacy of application nocardia erythraea cell wall skeleton in the treatment of per⁃sistent cervical infection with human papillomavirus in patients with cervical intraepithelial neoplasia

作　　者：徐冰南[1] 金亚彬 李枚格 XU Bing-nan;JIN Ya-bin;LI Mei-ge(The First People’s Hospital of Foshan,Fos-han 528000,China)

机构地区：[1]佛山市第一人民医院,佛山528000

出　　处：《妇产与遗传（电子版）》2022年第1期38-41,共4页Obstetrics-Gynecology and Genetics (Electronic Edition)

摘　　要：目的探讨宫颈局部外用红色诺卡氏菌细胞壁骨架制剂(nocardiarubra cell wall skeleton,Nr⁃CWS)治疗宫颈上皮内瘤变患者宫颈持续感染人乳头瘤病毒(human papilloma virus,HPV)的临床疗效。方法选取佛山市第一人民医院2018年4月至2020年5月收治的198例HPV持续感染一年以上的CINⅠ~CINⅡ期患者,采用随机数表法分为研究组与对照组,研究组采用Nr⁃CWS治疗,对照组采用保妇康栓治疗。治疗6个月后检测两组患者HPV,比较两组疗效。结果使用Nr⁃CWS在治疗6个月后的治愈59例,有效73例,治愈率达到60.2%,有效率达到74.5%,相比对照组均有显著提升(χ2=23.64,χ2=42.81,P<0.0001),且针对各种HPV型别Nr⁃CWS均表现出较好的治疗效果。结论宫颈局部外用Nr⁃CWS治疗HPV持续性感染疗效显著,能够有效清除多种型别HPV感染,可能是一种理想的治疗方法。Objective To investigate the clinical effect of topical application of Nocardia erythraea cell wall skeleton(Nr⁃CWS)on patients with cervical intraepithelial neoplasia associated with persistence of human papillomavirus(HPV)infections.Methods A total of 198 CIN1⁃CIN2 patients with persistent HPV infections above a year who were admitted to the First People’s Hospital of Foshan from April 2018 to May 2020 were selected,and randomly divided into a study group and a control group.The study group was treated with Nr⁃CWS,compared to the control group with Baofukangshuan treatment.After 6 months treatment,the curative and effective rates of Nr⁃CWS were examined by detecting HPV in both groups.Results The curative rate(60.2%)and effective rate(74.5%)of Nr⁃CWS were significantly improved(χ2=23.64,χ2=42.81,P<0.0001),concomitant with better therapeutic effect for various HPV types.Conclusion Nr⁃CWS is a promising treatment for persistent HPV infections,particularly in removing multiple HPV types.

关 键 词：红色诺卡氏菌细胞壁骨架制剂 宫颈上皮内瘤变 人乳头瘤病毒 

分 类 号：R737.33[医药卫生—肿瘤]